Sorry for the absence! I’ve been hard at work. On what?
Let’s see…
I have a new financial software package I’m hoping to unveil soon. It’s called Godel and you can request a beta invite by filling this form out: https://forms.gle/QW2NEeuPPzoz7Ri57
I hope Godel will provide a refactored AWS-style version of what Bloomberg is today. The Bloomberg terminal has a lot of issues I won’t enumerate, and every client knows what they are. Usage-based pricing (as well as a free tier), native web access and so many more advantages will propel Godel to success.
Druglike also has had some updates including a more rapid time-to-start for screening. Try it out at www.druglike.com. I’m hoping to add molecular dynamics, pharmacokinetics and other simulators to the total package at some point. Other upgrades would include fiat payment, API, and of course, a decentralized compute strategy. One idea is to use webworkers/wasm to bootstrap your own simulation jobs, where you can add your friends’ local compute to your ‘workspace’. A private folding@home.
As I’ve said many times, Druglike is not a drug company in any way, shape or form, and the FTC has not suggested it is. Druglike is software and never touches an actual tangible thing, like a chemical or a mouse or god forbid, a prescription medicine.
So what was that news about? My lawyers and I missed a deadline to file a routine update with the FTC and schedule a meeting. That will be done. I’m not in contempt and won’t be ‘in trouble’ over this. Mea culpa. It turns out some people on my team were sick during the response period and there was some telephone tag. Total non-event, but don’t tell that to the media who insists this is somehow ‘news’.
Anyway, I’ve worked on some other software for fun. On my github, you will find a ChatGPT-powered recursive story/book generator: https://github.com/martinshkreli/bookgen. “I” wrote a 47-page novella that I’m going to toss on Kindle. That should be funny.
I made a terminal-based quote monitor which is pretty funny. Real-time quotes in your command prompt. This is not the Godel master project, just something for fun. https://github.com/martinshkreli/stocks
I’m also on wakatime if you want to follow me there: https://wakatime.com/@martinshkreli
Outside of software, I’ve been paying attention to the rest of the world. Some stocks look cheap, others don’t. Not much has changed there. I’ve liked TSLA 0.00%↑ and META 0.00%↑ at recent prices. I talk a lot about this stuff on my livestreams on YouTube (https://www.youtube.com/channel/UCjYKsjt-7EDU78KEcVbhYnQ) or Twitch (https://www.twitch.tv/martinshkreli2022). I looked at ATVI 0.00%↑ ELV 0.00%↑ ZNTL 0.00%↑ and other stocks recently. You can find updated models on Github, including a small hedge fund tracker: https://www.github.com/martinshkreli/models
I am to please, so let me know what you’d like to see more content about, including analysis of specific stocks. I may be doing a fun podcast with a few friends. This would be mostly comedy-oriented and not focused on things like this recent paper from a Chinese group on quantum computing: https://arxiv.org/pdf/2212.12372.pdf. It was cool to try AWS Braket. It’d be nice to try to do what the Chinese authors did on a Rigetti. When I have time…
I have an old hard drive of my finance and chemistry lessons, so expect those to be uploaded again. I’m thinking about the right way to continue that series.
Finally, I’ve been enjoying the video game “Rust”. It’s a very immersive survival game that speaks to my OCD/hoarder nature. I need to quit!
Until next time,
Martin Shkreli
Hey Martin loving these newsletter style updates! You reminded me of a friend of mine 83 years of age, retired librarian. I've known him for 10 years by now - his mind is sharp as ever, he keeps a very busy social live and has lots of passion projects going on! He also has a monthly newsletter called Brownian Movement (last name is Brown!), very similar to yours. Seeing someone like this gives me hope for growing old... Keep it up! :)
Dmitry K
Hi, I feel like I've missed the huge +48% rise in HongKong HSI Index as any western outlet seemed not to mention it much or at all - looking at you Bloomberg News! Could only vaguely read about it in Goldman Sachs' newsletter. That's the kind of topics I'd love to get into, while every outlet I know practically ignored it - presented only the negative aspects.